Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUThe EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic Share XEyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUhttps://pharmaphorum.com/news/eyeing-dupixents-territory-leo-pharma-files-tralokinumab-in-eu/
Towards Patient Centricity: LEO PharmaIndustry plays a pivotal role in making sure patient needs are not overlooked by the wider healthcare community. Share XTowards Patient Centricity: LEO Pharmahttps://pharmaphorum.com/views-analysis-patients/towards-patient-centricity-leo-pharma/
Smartphone app provides skin cancer early warning serviceThe makers of a smartphone app are hoping that it could be used to play a crucial role Share XSmartphone app provides skin cancer early warning servicehttps://pharmaphorum.com/news/smartphone-app-provides-skin-cancer-early-warning-service/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Deep Dive: Access and CommercialisationIn this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing Share XDeep Dive: Access and Commercialisationhttps://pharmaphorum.com/digital/pharma-access-commercialisation/
LEO Pharma teams up with Wearifi for dermatology research wearableLEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential Share XLEO Pharma teams up with Wearifi for dermatology research wearablehttps://pharmaphorum.com/news/leo-pharma-wearifi-dermatology/
Almirall buys Allergan’s derma portfolioAlmirall is expanding its business by buying Allergan’s dermatology portfolio. The Spanish pharma company will buy five brands Share XAlmirall buys Allergan’s derma portfoliohttps://pharmaphorum.com/news/almirall-buys-allergans-derma-portfolio/
LEO Pharma acquires Bayer’s dermatology unitDanish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer’s global Share XLEO Pharma acquires Bayer’s dermatology unithttps://pharmaphorum.com/news/leo-pharma-acquires-bayers-dermatology-unit/
The sky’s the limit for LEO Pharma’s R&D hubAs part of pharmaphorum’s eye-on-innovation series of interviews, Richard Staines speaks to Michael Sierra, Vice President of LEO Share XThe sky’s the limit for LEO Pharma’s R&D hubhttps://pharmaphorum.com/views-analysis-digital/skys-limit-leo-pharma-rd-hub/
